These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6452764)

  • 1. [Behavior of plasminogen in prostatic carcinoma treated with cytonal].
    Oehler D; Kätzel R; Brunner HP
    Z Urol Nephrol; 1980 Dec; 73(12):923-9. PubMed ID: 6452764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
    Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R
    Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
    Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fibrinolytic system in experimental prostate tumor.
    Al-Mondhiry H; Drago J; Bartholomew MJ
    Thromb Haemost; 1986 Oct; 56(2):133-6. PubMed ID: 3810552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor].
    Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):86-8. PubMed ID: 8756739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fibrinolysis in prostate carcinomas of varying grades of differentiation with respect to estrogen therapy and castration].
    Oehler D; Feustel A
    Z Urol Nephrol; 1980 Mar; 73(3):201-10. PubMed ID: 7434984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Liver damage in hormone therapy of prostate cancer].
    Zade W; Schott H
    Z Urol Nephrol; 1987 Mar; 80(3):177-9. PubMed ID: 3604474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis in patients with metastatic carcinoma of the prostate gland.
    DOLAZ EJ; DOLEHIDE RA; FRIEDMAN IA
    Ill Med J; 1955 Mar; 107(3):142-4. PubMed ID: 14353517
    [No Abstract]   [Full Text] [Related]  

  • 9. [Long-term study of plasma testosterone levels in hormone therapy of prostatic cancer].
    Hájek J; Hanselová M; Vrubel F
    Vnitr Lek; 1981 Sep; 27(9):852-60. PubMed ID: 7293030
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasma concentrations of fosfestrol as well as diethylstilbestrol on their conjugates following intravenous administration on prostatic carcinoma patients].
    Oelschläger H; Rothley D; Dunzendorfer U
    Arzneimittelforschung; 1986 Aug; 36(8):1284-9. PubMed ID: 3778569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Massive pleural effusions from prostatic lymphangitic carcinomatosis: resolution with endocrine therapy.
    Heffner JE; Duffey DJ; Schwarz MI
    Arch Intern Med; 1982 Feb; 142(2):375-6. PubMed ID: 7059263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].
    Uchida K; Takeshima H; Kikuchi K; Shimazui T; Miyanaga N; Kawai K; Akaza H; Tsuchiya A; Noguchi R; Hattori K; Manabe F; Matsuki K; Suzuki R; Ishikawa S; Kondo F; Kobayashi T; Koiso K
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1179-87. PubMed ID: 9679581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Euglobulin lysis time method (author's transl)].
    Kazama M
    Rinsho Byori; 1976 Apr; 24(4):316-20. PubMed ID: 132550
    [No Abstract]   [Full Text] [Related]  

  • 16. Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
    Seal US; Doe RP; Byar DP; Corle DK
    Cancer; 1976 Sep; 38(3):1108-17. PubMed ID: 182348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hematochemical findings in young workers exposed to carbon disulfide. I. The behavior of fibrinolysis].
    Visconti E; Vidaković A; Cavalleri A; Visnjic V; Maugeri U; Rezman I
    Med Lav; 1966 Nov; 57(11):667-76. PubMed ID: 4228562
    [No Abstract]   [Full Text] [Related]  

  • 18. [Combined hormone and chemotherapy for the patients with advanced prostate cancer].
    Uekado Y; Hirano A; Inagaki T; Hiroi A; Watanabe T
    Gan To Kagaku Ryoho; 1995 Jul; 22(8):1041-5. PubMed ID: 7611755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma.
    Klotz L; McNeill I; Fleshner N
    J Urol; 1999 Jan; 161(1):169-72. PubMed ID: 10037391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience of hormone therapy to bone metastatic prostate cancer.
    Wakisaka M; Nomura K
    Int J Urol; 2006 May; 13(5):550-4. PubMed ID: 16771724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.